RCUS Arcus Biosciences Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Recent Analyst Ratings for Arcus Biosciences Inc.

Date	Price Target	Rating	Analyst
2/26/2025	$18.00 → $24.00	Neutral → Buy	H.C. Wainwright
10/21/2024	$20.00	Neutral	H.C. Wainwright
10/8/2024	$29.00	Overweight	Wells Fargo
11/18/2022	$33.00	Neutral	BofA Securities
10/11/2022	$40.00	Overweight	Morgan Stanley
11/19/2021	$42.00 → $53.00	Buy	Citigroup
11/19/2021	$48.00 → $60.00	Overweight	Barclays
11/18/2021	$68.00 → $100.00	Outperform	SVB Leerink
11/9/2021	$45.00 → $48.00	Overweight	Barclays
10/15/2021	$57.00	Buy	BTIG Research

See more ratings

Arcus Biosciences Inc.

Peers

Recent Analyst Ratings for Arcus Biosciences Inc.

Arcus Biosciences Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Perlman Andrew J was granted 13,300 shares, increasing direct ownership by 45% to 42,625 units (SEC Form 4)

Director Falberg Kathryn E was granted 13,300 shares, increasing direct ownership by 24% to 68,600 units (SEC Form 4)

Director Machado Patrick was granted 13,300 shares, increasing direct ownership by 53% to 38,600 units (SEC Form 4)

Director Ribas Antoni was granted 13,300 shares, increasing direct ownership by 44% to 43,650 units (SEC Form 4)

Director Lacey David L. was granted 13,300 shares, increasing direct ownership by 23% to 70,952 units (SEC Form 4)

Director Kaneko Yasunori was granted 13,300 shares, increasing direct ownership by 66% to 33,300 units (SEC Form 4)

Director Lambert Nicole was granted 13,300 shares, increasing direct ownership by 55% to 37,300 units (SEC Form 4)

Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

Large owner Gilead Sciences, Inc. bought $14,999,996 worth of shares (1,363,636 units at $11.00), increasing direct ownership by 5% to 31,424,760 units (SEC Form 4)

Arcus Biosciences Inc. SEC Filings

Arcus Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

Arcus Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

SEC Form SCHEDULE 13G filed by Arcus Biosciences Inc.

SEC Form 10-Q filed by Arcus Biosciences Inc.

Arcus Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by Arcus Biosciences Inc.

SEC Form DEF 14A filed by Arcus Biosciences Inc.

Amendment: SEC Form SCHEDULE 13D/A filed by Arcus Biosciences Inc.

SEC Form S-8 filed by Arcus Biosciences Inc.

SEC Form 10-K filed by Arcus Biosciences Inc.